CN109847109A - A kind of contact lens carrying medicine - Google Patents
A kind of contact lens carrying medicine Download PDFInfo
- Publication number
- CN109847109A CN109847109A CN201811060344.6A CN201811060344A CN109847109A CN 109847109 A CN109847109 A CN 109847109A CN 201811060344 A CN201811060344 A CN 201811060344A CN 109847109 A CN109847109 A CN 109847109A
- Authority
- CN
- China
- Prior art keywords
- contact lens
- compound
- antibiotic
- lens according
- soft
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 230000003115 biocidal effect Effects 0.000 claims abstract description 44
- 229940079593 drug Drugs 0.000 claims abstract description 21
- 238000005253 cladding Methods 0.000 claims abstract description 9
- -1 N-vinyl pyrrolidone class compound Chemical class 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 4
- 239000003429 antifungal agent Substances 0.000 claims description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 4
- 229930182478 glucoside Natural products 0.000 claims description 4
- 150000008131 glucosides Chemical class 0.000 claims description 4
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 4
- 229940041033 macrolides Drugs 0.000 claims description 4
- 229960001699 ofloxacin Drugs 0.000 claims description 4
- 229920001610 polycaprolactone Polymers 0.000 claims description 4
- 239000004632 polycaprolactone Substances 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 3
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 3
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 3
- 229960003942 amphotericin b Drugs 0.000 claims description 3
- 229960002626 clarithromycin Drugs 0.000 claims description 3
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 3
- 239000000017 hydrogel Substances 0.000 claims description 3
- 229960004130 itraconazole Drugs 0.000 claims description 3
- 229960002422 lomefloxacin Drugs 0.000 claims description 3
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 claims description 3
- 229920000191 poly(N-vinyl pyrrolidone) Chemical class 0.000 claims description 3
- 229920002401 polyacrylamide Polymers 0.000 claims description 3
- 229920001296 polysiloxane Polymers 0.000 claims description 3
- 229920002635 polyurethane Polymers 0.000 claims description 3
- 239000004814 polyurethane Substances 0.000 claims description 3
- 229960000707 tobramycin Drugs 0.000 claims description 3
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims description 3
- RZLHGQLYNZQZQQ-UHFFFAOYSA-N 1-ethyl-6-fluoro-4-oxo-7-pyrrol-1-ylquinoline-3-carboxylic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1C=CC=C1 RZLHGQLYNZQZQQ-UHFFFAOYSA-N 0.000 claims description 2
- MGQLHRYJBWGORO-LLVKDONJSA-N Balofloxacin Chemical compound C1[C@H](NC)CCCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC MGQLHRYJBWGORO-LLVKDONJSA-N 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- AIJTTZAVMXIJGM-UHFFFAOYSA-N Grepafloxacin Chemical compound C1CNC(C)CN1C(C(=C1C)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 AIJTTZAVMXIJGM-UHFFFAOYSA-N 0.000 claims description 2
- NUAQIRUAZSJTAI-YRPZDAAMSA-N O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@H](N)CC(C)C)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@H](N)CC(C)C)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 NUAQIRUAZSJTAI-YRPZDAAMSA-N 0.000 claims description 2
- 108010093965 Polymyxin B Proteins 0.000 claims description 2
- URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 claims description 2
- 229930192786 Sisomicin Natural products 0.000 claims description 2
- 229950000805 balofloxacin Drugs 0.000 claims description 2
- 229960003405 ciprofloxacin Drugs 0.000 claims description 2
- QGPKADBNRMWEQR-UHFFFAOYSA-N clinafloxacin Chemical compound C1C(N)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1Cl QGPKADBNRMWEQR-UHFFFAOYSA-N 0.000 claims description 2
- 229950001320 clinafloxacin Drugs 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 229960000642 grepafloxacin Drugs 0.000 claims description 2
- 229950003514 irloxacin Drugs 0.000 claims description 2
- 229960000808 netilmicin Drugs 0.000 claims description 2
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 claims description 2
- 229960001180 norfloxacin Drugs 0.000 claims description 2
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims description 2
- 108700014375 norvancomycin Proteins 0.000 claims description 2
- 229920000024 polymyxin B Polymers 0.000 claims description 2
- 229960005266 polymyxin b Drugs 0.000 claims description 2
- 229960005456 sisomicin Drugs 0.000 claims description 2
- URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 claims description 2
- 229960004954 sparfloxacin Drugs 0.000 claims description 2
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 claims description 2
- 229960000497 trovafloxacin Drugs 0.000 claims description 2
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 claims description 2
- 150000003952 β-lactams Chemical class 0.000 claims description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- RPABDKTXMKOGKI-OYTUFZPASA-N 6-methyl-n-[2-[(2s,5s,8s,11s,14s,17s,20s,23s)-8,11,14,20-tetrakis(2-aminoethyl)-5-[(1r)-1-hydroxyethyl]-17,23-bis(2-methylpropyl)-3,6,9,12,15,18,21,24-octaoxo-1,4,7,10,13,16,19,22-octazacyclotetracos-2-yl]ethyl]octanamide Chemical compound CCC(C)CCCCC(=O)NCC[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H]([C@@H](C)O)NC1=O RPABDKTXMKOGKI-OYTUFZPASA-N 0.000 claims 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims 1
- 229930186147 Cephalosporin Natural products 0.000 claims 1
- 108010078777 Colistin Proteins 0.000 claims 1
- 108090000204 Dipeptidase 1 Proteins 0.000 claims 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 claims 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 1
- 229930182566 Gentamicin Natural products 0.000 claims 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 1
- 229930182555 Penicillin Natural products 0.000 claims 1
- 235000014676 Phragmites communis Nutrition 0.000 claims 1
- 108010059993 Vancomycin Proteins 0.000 claims 1
- 150000001336 alkenes Chemical class 0.000 claims 1
- 229960004099 azithromycin Drugs 0.000 claims 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 1
- 150000003851 azoles Chemical class 0.000 claims 1
- 102000006635 beta-lactamase Human genes 0.000 claims 1
- 229940124587 cephalosporin Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229960004273 floxacillin Drugs 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 229960002518 gentamicin Drugs 0.000 claims 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims 1
- 229960003165 vancomycin Drugs 0.000 claims 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 abstract description 10
- 210000004087 cornea Anatomy 0.000 abstract description 9
- 239000003242 anti bacterial agent Substances 0.000 abstract description 4
- 229940088710 antibiotic agent Drugs 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 229920002521 macromolecule Polymers 0.000 abstract description 2
- 238000002513 implantation Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003781 beta lactamase inhibitor Chemical group 0.000 description 3
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 3
- 206010014801 endophthalmitis Diseases 0.000 description 3
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 206010023683 lagophthalmos Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- NJCJBUHJQLFDSW-UHFFFAOYSA-N Rufloxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 NJCJBUHJQLFDSW-UHFFFAOYSA-N 0.000 description 1
- UOBPHQJGWSVXFS-UHFFFAOYSA-N [O].[F] Chemical compound [O].[F] UOBPHQJGWSVXFS-UHFFFAOYSA-N 0.000 description 1
- 150000003926 acrylamides Chemical class 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- IYNDLOXRXUOGIU-LQDWTQKMSA-M benzylpenicillin potassium Chemical class [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 IYNDLOXRXUOGIU-LQDWTQKMSA-M 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 231100000269 corneal opacity Toxicity 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- 229960004062 rufloxacin Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Abstract
The invention discloses a kind of contact lens for carrying medicine, and the drug-loaded layer including contact lens,soft and cladding contact lens,soft, drug-loaded layer is made of antibiotic with the carrier for being loaded with antibiotic.Of the invention is loaded on the contact lens of antibiotics, antibiotics is on the form appendix to contact lens that is wrapped in macromolecule carrier, after patient wears, antibiotic slow release in suffering from eye, certain intraocular concentration is maintained, has the function that prevent the postoperative ocular of artificial cornea and intraocular inflammation.
Description
Technical field
The present invention relates to artificial cornea implanted prosthetics fields, especially a kind of for feeling after preventing artificial cornea implant surgery
The load medicine contact lense of dye.
Background technique
Artificial cornea is a kind of special refractive apparatus made of alloplastic material for replacing muddy cornea tissue,
By performing the operation, eye is suffered from implantation, to obtain certain eyesight.Artificial cornea implantation number of cases is greatly improved in recent years, wherein one
It is a the reason is that patient after surgery all the life use antibacterium and antimycotic antibiotic so that the incidence of postoperative endophthalmitis significantly under
Drop, although this measure is remarkably decreased the incidence of postoperative bacterial endophthalmitis, bacterial endophthalmitis is still artificial cornea
A big worry after implantation, the incidence of document report this complication in past 10 years is between 3.2%~16.7%；Separately
On the one hand postoperative lifelong using antibiotic, the compliance of patient is a big problem.
Summary of the invention
Based on the above issues, one kind is provided it is an object of the invention to overcome in place of above-mentioned the deficiencies in the prior art can be
The load medicine contact lens of slow release antibiotic in patient's eye is avoided that patient is postoperative and needs that antibiotic is repeatedly added dropwise daily
The problem of eyedrops.
To achieve the above object, the technical scheme adopted by the invention is as follows:
A kind of contact lens carrying medicine, the drug-loaded layer including contact lens,soft and the cladding contact lens,soft are described
Drug-loaded layer is made of antibiotic with the carrier for being loaded with antibiotic.
As advanced optimizing for above scheme, the material of the contact lens,soft is polymethylacrylic acid-hydroxyl ethyl ester, gathers
Acrylamides, poly N-vinyl pyrrolidone class compound, polyacrylacid ester compounds, polysiloxanes PS class
Close object, polyurethane P class compound or silicone-hydrogel.
As advanced optimizing for above scheme, the antibiotic be quino ketone compounds, macrolides compound,
At least one of beta-lactam compound, glucoside-containing component, polypeptide compounds and antifungal drug.
As advanced optimizing for above scheme, the quino ketone compounds are Norfloxacin, Ciprofloxacin, oxygen fluorine sand
Star, lavo-ofloxacin, fleraxacin, Irloxacin, Lomefloxacin, Sparfloxacin, Grepafloxacin, Rufloxacin, Clinafloxacin,
At least one of balofloxacin and trovafloxacin.
As advanced optimizing for above scheme, the macrolides compound be roxithromycin, clarithromycin and Ah
At least one of miramycin.
As advanced optimizing for above scheme, the beta-lactam compound is penicilline compounds, cephalo bacterium
Chlorins compound, novel ss-lactam class compound, beta-lactam compound and beta-lactamase inhibitor form compound
At least one of preparation.
As advanced optimizing for above scheme, the glucoside-containing component is amikacin, tobramycin, celebrates greatly
At least one of mycin, Netilmicin, sisomicin and streptomysin.
As advanced optimizing for above scheme, the polypeptide compounds are polymyxin B, polymyxin e, mould through the ages
At least one of element, Norvancomycin and wall mycin.
As advanced optimizing for above scheme, the antifungal drug be amphotericin B, Fluconazole, Itraconazole and
At least one of 5-flurocytosine.
As advanced optimizing for above scheme, the carrier is glycerol propoxylate triacrylate, polycaprolactone, shell
In glycan, poly lactide-glycolide acid, polymethylacrylic acid-hydroxyl ethyl ester, ethyl cellulose and Utech S-100 extremely
Few one kind.
In conclusion the invention has the benefit that
Of the invention is loaded on the contact lens of antibiotics, and antibiotics is to be wrapped in macromolecule carrier
In form appendix to contact lens on, after patient wears, antibiotic slow release in suffering from eye remains certain intraocular dense
Degree has the function that prevent the postoperative ocular of artificial cornea and intraocular inflammation；The present invention is antibiotic-loaded in the postoperative needs of patient
On the contact lens,soft of wearing, after patient wears, antibiotic is sustained from contact lens,soft with certain rate and is come out, and maintains eye
The antibiotic concentration of table has the function that prevent entophthamia more than minimum action concentration.
Detailed description of the invention
Fig. 1 is the structural schematic diagram of the contact lens of load medicine of the invention；
Wherein, 1, contact lens,soft, 2, drug-loaded layer, 3, carrier.
Specific embodiment
To better illustrate the object, technical solutions and advantages of the present invention, below in conjunction with the drawings and specific embodiments pair
The present invention is described further.
Embodiment 1
The contact lens of a kind of load medicine of the invention, as shown in Figure 1, including contact lens,soft 1 and cladding soft contact
The drug-loaded layer 2 of mirror 1, drug-loaded layer 2 are made of antibiotic with the carrier 3 for being loaded with antibiotic；
Wherein, the material of contact lens,soft 1 is polymethylacrylic acid-hydroxyl ethyl ester；Antibiotic is Lomefloxacin；Carrier 3 is
Glycerol propoxylate triacrylate.
Embodiment 2
The contact lens of a kind of load medicine of the invention, as shown in Figure 1, including contact lens,soft 1 and cladding soft contact
The drug-loaded layer 2 of mirror 1, drug-loaded layer 2 are made of antibiotic with the carrier 3 for being loaded with antibiotic；
Wherein, the material of contact lens,soft 1 is poly N-vinyl pyrrolidone class compound；Antibiotic is tobramycin；
Carrier 3 is the mixture of polycaprolactone and Utech S-100, and the mass ratio of the two is 1:3.
Embodiment 3
The contact lens of a kind of load medicine of the invention, as shown in Figure 1, including contact lens,soft 1 and cladding soft contact
The drug-loaded layer 2 of mirror 1, drug-loaded layer 2 are made of antibiotic with the carrier 3 for being loaded with antibiotic；
Wherein, the material of contact lens,soft 1 is silicone-hydrogel；Carrier 3 is chitosan；Antibiotic is for clarithromycin and through the ages
The mixture of mycin, the mass ratio of the two are 5:2.
Embodiment 4
The contact lens of a kind of load medicine of the invention, as shown in Figure 1, including contact lens,soft 1 and cladding soft contact
The drug-loaded layer 2 of mirror 1, drug-loaded layer 2 are made of antibiotic with the carrier 3 for being loaded with antibiotic；
Wherein, the material of contact lens,soft 1 is polysiloxanes PS class compound；Carrier 3 is polycaprolactone；Antibiotic is
The compound formulation of beta-lactam compound and beta-lactamase inhibitor composition, the wherein quality hundred of beta-lactamase inhibitor
Dividing content is 36%.
Embodiment 5
The contact lens of a kind of load medicine of the invention, as shown in Figure 1, including contact lens,soft 1 and cladding soft contact
The drug-loaded layer 2 of mirror 1, drug-loaded layer 2 are made of antibiotic with the carrier 3 for being loaded with antibiotic；
Wherein, the material of contact lens,soft 1 is polyurethane P class compound；Carrier 3 is poly lactide-glycolide acid；
Antibiotic is Itraconazole.
Embodiment 6
The contact lens of a kind of load medicine of the invention, as shown in Figure 1, including contact lens,soft 1 and cladding soft contact
The drug-loaded layer 2 of mirror 1, drug-loaded layer 2 are made of antibiotic with the carrier 3 for being loaded with antibiotic；
Wherein, the material of contact lens,soft 1 is the mixing of polymethylacrylic acid-hydroxyl ethyl ester and polyacrylamide compound
Object, wherein the mass ratio of the two is 1:4；Carrier 3 is poly lactide-glycolide acid；Antibiotic is lavo-ofloxacin, appropriate cloth
The mixture of mycin and amphotericin B, load medicine mass ratio of the three on carrier are 1:1:1；
The preparation method of above-mentioned contact lens,soft: existed with polymethylacrylic acid-hydroxyl ethyl ester and polyacrylamide compound
37 DEG C, under ultraviolet light trigger condition crosslinking copolymerization at contact lens,soft.
Above-mentioned contact lens,soft 1 forms load medicine in a manner of casting is blended or impregnates infiltration with the carrier 3 for being loaded with antibiotic
Contact lens.
Embodiment 7
After Preliminary Animal Experiment shows the contact lens implantation lagophthalmos of embodiment 6, the drug of release is in zero in lagophthalmos
Grade pharmacokinetics release, release time, which is up in 2 weeks, 2 weeks, can detect that testing drug (i.e. antibiotic) in rabbit aqueous humor
Concentration is in 3.6mg/ml or more.
Contact lens,soft of the invention is per se with art eye ocular after wet application of keratoprosthesis for corneal opacity unsuitable for keratoplasty and preliminary prevention
The function of infection.Experiment shows the contact lens,soft for being loaded with antibiotic of the invention in art eye with zero level pharmacokinetics energy
Slow release, it is sufficient to reach the minimum action concentration of antibiotic.It wears the present invention and carries medicine contact lens,soft, it is postoperative to solve patient
The lifelong compliance problem for using antibiotic, to further decrease the incidence of entophthamia.
Compared with prior art, the beneficial effects of the present invention are: by the way that antibiotic-loaded is day and night worn in patient is postoperative
On the contact lens,soft worn, antibiotic is made to suffer from eye surface slow release in patient to reach the minimum action concentration of antibiotic；
The present invention solves the problems, such as that patient is postoperative and repeatedly drips antibiotic ophthalmic liquid medicine daily, further decreases the plant of the artificial corneas such as entophthamia
Enter the incidence of postoperative complications.
Finally, it should be noted that the above embodiments are merely illustrative of the technical solutions of the present invention rather than protects to the present invention
The limitation of range is protected, although the invention is described in detail with reference to the preferred embodiments, those skilled in the art should
Understand, it can be with modification or equivalent replacement of the technical solution of the present invention are made, without departing from the essence of technical solution of the present invention
And range.
Claims (10)
1. a kind of contact lens for carrying medicine, which is characterized in that the load including contact lens,soft and the cladding contact lens,soft
Medicine layer, the drug-loaded layer are made of antibiotic with the carrier for being loaded with antibiotic.
2. contact lens according to claim 1, which is characterized in that the material of the contact lens,soft is poly- methyl-prop
Olefin(e) acid-hydroxyl ethyl ester, polyacrylamide compound, poly N-vinyl pyrrolidone class compound, polyacrylacid ester compounds,
Polysiloxanes PS class compound, polyurethane P class compound or silicone-hydrogel.
3. contact lens according to claim 1, which is characterized in that the antibiotic is quino ketone compounds, greatly
In macrolides, beta-lactam compound, glucoside-containing component, polypeptide compounds and antifungal drug
It is at least one.
4. contact lens according to claim 3, which is characterized in that the quino ketone compounds be Norfloxacin,
Ciprofloxacin, Ofloxacin, lavo-ofloxacin, fleraxacin, Irloxacin, Lomefloxacin, Sparfloxacin, Grepafloxacin, reed
At least one of Flucloxacillin, Clinafloxacin, balofloxacin and trovafloxacin.
5. contact lens according to claim 3, which is characterized in that the macrolides compound is that Luo Hong is mould
At least one of element, clarithromycin and azithromycin.
6. contact lens according to claim 3, which is characterized in that the beta-lactam compound is penicillins
Compound, cephalosporin compound, novel ss-lactam class compound, beta-lactam compound and beta-lactamase inhibit
At least one of the compound formulation of agent composition.
7. contact lens according to claim 3, which is characterized in that the glucoside-containing component is A meter Ka
At least one of star, tobramycin, gentamicin, Netilmicin, sisomicin and streptomysin.
8. contact lens according to claim 3, which is characterized in that the polypeptide compounds are polymyxin B, more
At least one of Coli-Mycin S, vancomycin, Norvancomycin and wall mycin.
9. contact lens according to claim 3, which is characterized in that the antifungal drug is amphotericin B, fluorine health
At least one of azoles, Itraconazole and 5-flurocytosine.
10. contact lens according to claim 1, which is characterized in that the carrier is three acrylic acid of glycerol propoxylate
Ester, polycaprolactone, chitosan, poly lactide-glycolide acid, polymethylacrylic acid-hydroxyl ethyl ester, ethyl cellulose and outstanding
At least one of special surprise S-100.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811060344.6A CN109847109A (en) | 2018-09-11 | 2018-09-11 | A kind of contact lens carrying medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811060344.6A CN109847109A (en) | 2018-09-11 | 2018-09-11 | A kind of contact lens carrying medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109847109A true CN109847109A (en) | 2019-06-07 |
Family
ID=66889741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811060344.6A Pending CN109847109A (en) | 2018-09-11 | 2018-09-11 | A kind of contact lens carrying medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109847109A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112316219A (en) * | 2020-09-29 | 2021-02-05 | 浙江大学 | Anti-adhesion hydrogel-silk scaffold composite membrane and preparation and application thereof |
| CN112415773A (en) * | 2020-12-03 | 2021-02-26 | 山东省眼科研究所 | Medicine-carrying contact lens for promoting corneal epithelium injury repair and preparation method thereof |
| WO2022139749A3 (en) * | 2020-12-21 | 2022-08-18 | T.C. Marmara Üni̇versi̇tesi̇ | A method for thi̇el-behnke corneal dystrophy (tbcd) and an artificial tissue scaffold produced by said method |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060280774A1 (en) * | 1995-06-02 | 2006-12-14 | Allergan, Inc. | Compositions and methods for treating glaucoma |
| CN101502458A (en) * | 2009-03-03 | 2009-08-12 | 温州医学院眼视光研究院 | Therapeutic corneal contact lens |
| CN103025312A (en) * | 2008-12-11 | 2013-04-03 | 麻省理工学院 | Contact lens drug delivery device |
| US20150157563A1 (en) * | 2013-10-17 | 2015-06-11 | Jade Therapeutics, Inc | Ocular composition and method |
| CN206515567U (en) * | 2017-03-06 | 2017-09-22 | 重庆医药高等专科学校 | One kind carries property of medicine contact lens |
-
2018
- 2018-09-11 CN CN201811060344.6A patent/CN109847109A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060280774A1 (en) * | 1995-06-02 | 2006-12-14 | Allergan, Inc. | Compositions and methods for treating glaucoma |
| CN103025312A (en) * | 2008-12-11 | 2013-04-03 | 麻省理工学院 | Contact lens drug delivery device |
| CN101502458A (en) * | 2009-03-03 | 2009-08-12 | 温州医学院眼视光研究院 | Therapeutic corneal contact lens |
| US20150157563A1 (en) * | 2013-10-17 | 2015-06-11 | Jade Therapeutics, Inc | Ocular composition and method |
| CN206515567U (en) * | 2017-03-06 | 2017-09-22 | 重庆医药高等专科学校 | One kind carries property of medicine contact lens |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112316219A (en) * | 2020-09-29 | 2021-02-05 | 浙江大学 | Anti-adhesion hydrogel-silk scaffold composite membrane and preparation and application thereof |
| CN112316219B (en) * | 2020-09-29 | 2022-05-10 | 浙江大学 | Anti-adhesion hydrogel-silk scaffold composite membrane and preparation and application thereof |
| CN112415773A (en) * | 2020-12-03 | 2021-02-26 | 山东省眼科研究所 | Medicine-carrying contact lens for promoting corneal epithelium injury repair and preparation method thereof |
| WO2022139749A3 (en) * | 2020-12-21 | 2022-08-18 | T.C. Marmara Üni̇versi̇tesi̇ | A method for thi̇el-behnke corneal dystrophy (tbcd) and an artificial tissue scaffold produced by said method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lim et al. | Therapeutic contact lenses in the treatment of corneal and ocular surface diseases—a review | |
| CN109847109A (en) | A kind of contact lens carrying medicine | |
| BR0111056A (en) | Ophthalmic device, and method for implanting, through an eye incision, an ophthalmic device | |
| US20220110959A1 (en) | Compositions and Methods for Reducing Oxidative Damage | |
| Pape | Intracapsular and extracapsular technique of lens implantation with Healon® | |
| WO2010111528A4 (en) | Glaucoma shunts with flow management and improved surgical performance | |
| Nagy et al. | Laser refractive cataract surgery with a femtosecond laser after penetrating keratoplasty: case report | |
| Lorenz et al. | Visual results in congenital cataract with the use of contact lenses | |
| Amayem et al. | Bacterial keratitis after photorefractive keratectomy | |
| Basti et al. | Prospective evaluation of corneal endothelial cell loss after pediatric cataract surgery | |
| Zhang et al. | Femtosecond laser-assisted endokeratophakia using allogeneic corneal lenticule in a rabbit model | |
| Er et al. | Retrospective comparison of surgical techniques to prevent secondary oopacification in pediatric cataracts | |
| Berk et al. | Electron microscopic evaluation of a gold glaucoma micro shunt after explantation | |
| KR101816277B1 (en) | Composition for treatment of corneal damage containing 7,8-dihydro-8-oxo-2'-deoxyguanosine or pharmaceutically acceptable salts thereof as an active ingredient | |
| Shirai et al. | Histology and immunohistochemistry of fibrous posterior capsule opacification in an infant | |
| CA3148416A1 (en) | Contact lens and mold for manufacturing same | |
| Yuan et al. | The efficacy and safety of a novel posterior scleral reinforcement device in rabbits | |
| CN209984655U (en) | Medicine-carrying corneal contact lens | |
| Reddy et al. | Successful management of Burkholderia cepacia keratitis after LASIK | |
| CN108348455B (en) | Therapeutic use of sterile aqueous ophthalmic solutions | |
| Eidy et al. | Delivery of fluorescein to the anterior chamber using the corneal collagen shield | |
| US20120046332A1 (en) | Compositions and methods for treating corneal haze | |
| WO2002080915A3 (en) | Composition for the treatment of night sight problems (halos, coma and glare) comprising aceclidine | |
| Namiki et al. | Localized liquefied after-cataract | |
| US10813943B2 (en) | Therapeutic use of a sterile aqueous ophthalmic solution |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20201231 Address after: 510000 B01-1, 2nd floor, building B, No.2 Ruitai Road, Guangzhou high tech Industrial Development Zone, Guangzhou City, Guangdong Province Applicant after: Guangdong Jiashi Meiyue Biotechnology Co.,Ltd. Address before: 510000 3307, building E19, huiwenyi street, Liwan District, Guangzhou City, Guangdong Province Applicant before: Teng Yuchi |
|
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 510000 B01-1, 2nd floor, building B, No.2 Ruitai Road, Guangzhou high tech Industrial Development Zone, Guangzhou City, Guangdong Province Applicant after: Guangdong Jiayue Meishi Biotechnology Co.,Ltd. Address before: 510000 B01-1, 2nd floor, building B, No.2 Ruitai Road, Guangzhou high tech Industrial Development Zone, Guangzhou City, Guangdong Province Applicant before: Guangdong Jiashi Meiyue Biotechnology Co.,Ltd. |